← Back to Clinical Trials
Recruiting Phase 2 NCT06312813

Evaluating Use of Topical Imipramine and Amitriptyline in Reducing Ultraviolet B Light-Induced Redness in Patients With Rosacea

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

Condition Rosacea
Sponsor Wright State University
Study Type INTERVENTIONAL
Phase Phase 2
Enrollment 48
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2024-02-27
Completion 2028-12-01
Interventions
ImipramineAmitriptylineVehicle

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

Rosacea is a common skin condition associated with easy blushing and red face; many patients with rosacea react to sunlight with increased redness. The purpose of this study is to determine if the use of a topical medication will help reduce sunlight induced redness and irritation in patients with rosacea.

Eligibility Criteria

Inclusion Criteria: * Fitzpatrick Skin Type I - IIII * Self-identified rosacea or no history of flushing/blushing for controls * Able to provide medical history and list of medications -- control subjects will not be allowed to take medications that are known to be photosensitizers. Exclusion Criteria: * Using imipramine, amitriptyline or any other tricyclic antidepressant (oral or topical) * Using topical anti-inflammatory (within 1 week) or systemic agents (e.g. prednisone) * Large tattoos in the designated testing areas * Tanning bed use within last 3 months * Photodynamic Therapy or UCB treatments in past 3 months * Female Subjects: pregnant or nursing

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology
}